XBiotech Inc. (XBIT) is a Biotechnology: Pharmaceutical Preparations company listed on NASDAQ. In the last 30 days Quantisnow tracked 8 wire items for XBIT, including 4 insider trades, 2 press releases and news items and 2 SEC filings. The most recent was published Nov 13, 2026.
Financial highlights
Full financials- Net income, TTM
- -$43.59M
- Free cash flow, TTM
- -$41.00M
- Cash
- $105.04M
For the twelve months ended Sep 30, 2026, from SEC filings. Not investment advice.
News · 26 weeks11+700%
2026-05-172026-11-08
Mix990d
- Insider4(44%)
- SEC Filings3(33%)
- Other2(22%)
Activity · 52 weeks1715 active days
Tap a day to see what happenedEarningsInsiderAnalystFilings and news
Latest news
25 items- INSIDERDirector Simard John bought $143,409 worth of shares (70,000 units at $2.05), increasing direct ownership by 2% to 4,261,690 units (SEC Form 4)4 - XBiotech Inc. (0001626878) (Issuer)
- SECSEC Form 10-Q filed by XBiotech Inc.10-Q - XBiotech Inc. (0001626878) (Filer)
- INSIDERSEC Form 4 filed by XBiotech Inc.4 - XBiotech Inc. (0001626878) (Issuer)
- INSIDERSEC Form 3 filed by XBiotech Inc.3 - XBiotech Inc. (0001626878) (Issuer)
- INSIDERDirector Simard John bought $711,251 worth of shares (368,524 units at $1.93) (SEC Form 4)4 - XBiotech Inc. (0001626878) (Issuer)
- SECSEC Form 8-K filed by XBiotech Inc.8-K - XBiotech Inc. (0001626878) (Filer)
- PRXBiotech Announces Election of Sushma Shivaswamy and Jan-Paul Simard as Co-Chief Executive OfficersAUSTIN, Texas, Oct. 23, 2026 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ:XBIT) today announced that its Board of Directors have elected Jan-Paul Simard to serve as Co-Chief Executive Officer alongside CEO Dr. Sushma Shivaswamy, effective Oct. 23, 2026. "On behalf of the Board of Directors, we are excited to announce Dr. Sushma Shivaswamy and Jan-Paul Simard as Co-Chief Executive Officers," said Director Tevi Troy. "Their complementary skill sets, scientific acumen, and shared commitment to our mission position XBiotech to fully realize the potential of our True-Human antibody therapies." Dr. Shivaswamy has been with XBiotech for 17 years, having served as Senior Scientist, Director and Vic
- PRXBiotech Announces Positive Phase II Final Efficacy Results from Investigator-Sponsored TASKIN Trial in Refractory Metastatic Colorectal CancerInvestigator-sponsored study funded by the French National Cancer Institute (INCa) meets pre-specified primary efficacy success criterion with 61.3% 12-month overall survival. Exploratory Subgroup analysis reveals significant survival benefit in right-sided tumors. AUSTIN, Texas, Oct. 19, 2026 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ:XBIT) today announced positive final efficacy results from the randomized Phase II portion of the multicenter TASKIN clinical trial. The investigator-sponsored study—funded by the French National Cancer Institute (INCa) and coordinated by investigators at the Centre Georges-François Leclerc (CGFL) in Dijon, France—evaluated the addition of XBiotech’s anti-I
- SECSEC Form DEF 14A filed by XBiotech Inc.DEF 14A - XBiotech Inc. (0001626878) (Filer)
- SECSEC Form 10-Q filed by XBiotech Inc.10-Q - XBiotech Inc. (0001626878) (Filer)
- PRXBiotech Launches Phase II Clinical Trial Evaluating Vilamakitug for the Treatment of Active Axial SpondyloarthritisIND Application for V-SPINE Study Completes 30-Day FDA Review Without Clinical Hold, Clearing Path for U.S. Patient Enrollment AUSTIN, Texas, June 15, 2026 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ:XBIT) today announced that its Investigational New Drug (IND) application for V-SPINE (PT064), a Phase II, double-blind, placebo-controlled, randomized study evaluating the efficacy and safety of vilamakitug in participants with active axial spondyloarthritis, has successfully completed the U.S. Food and Drug Administration's (FDA) 30-day review period without a clinical hold. The study is now authorized to proceed with patient enrollment in the United States, marking the resumption of XBiotech
- SECSEC Form 10-Q filed by XBiotech Inc.10-Q - XBiotech Inc. (0001626878) (Filer)
- SECAmendment: SEC Form 10-K/A filed by XBiotech Inc.10-K/A - XBiotech Inc. (0001626878) (Filer)
- SECSEC Form 10-K filed by XBiotech Inc.10-K - XBiotech Inc. (0001626878) (Filer)
- SECSEC Form S-8 filed by XBiotech Inc.S-8 - XBiotech Inc. (0001626878) (Filer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by XBiotech Inc.SCHEDULE 13G/A - XBiotech Inc. (0001626878) (Subject)
- SECXBiotech Inc. filed SEC Form 8-K: Leadership Update8-K - XBiotech Inc. (0001626878) (Filer)
- SECSEC Form 10-Q filed by XBiotech Inc.10-Q - XBiotech Inc. (0001626878) (Filer)
- INSIDERSEC Form 4 filed by Director Rademaker Craig Evan4 - XBiotech Inc. (0001626878) (Issuer)
- INSIDERSEC Form 4 filed by Director Soffer David Spencer4 - XBiotech Inc. (0001626878) (Issuer)
- INSIDERSEC Form 4 filed by Director Kuendig Thomas Martin4 - XBiotech Inc. (0001626878) (Issuer)
- INSIDERSEC Form 4 filed by Director Troy Tevi David4 - XBiotech Inc. (0001626878) (Issuer)
- SECAmendment: XBiotech Inc. filed SEC Form 8-K: Leadership Update8-K/A - XBiotech Inc. (0001626878) (Filer)
- SECXBiotech Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Leadership Update, Financial Statements and Exhibits8-K - XBiotech Inc. (0001626878) (Filer)
- INSIDERSEC Form 3 filed by new insider Soffer David Spencer3 - XBiotech Inc. (0001626878) (Issuer)
XBIT FAQ
9 questionsWhat does XBiotech Inc. do?
XBiotech Inc., a biopharmaceutical company, discovers, develops, and commercializes True Human monoclonal antibodies for treating various diseases. The company focuses on developing a pipeline of antibody therapies for treating oncology, inflammatory conditions, and infectious diseases. It is also developing interleukin-1 alpha therapies to treat variety of medical conditions, such as cancer, stroke, heart attack, or arthritis; and True Human COVID-19 therapy for treating the COVID-19 mutant virus. In addition, the company provides clinical trial contract research operations to conduct two...What is the latest news on XBIT?
In the last 30 days Quantisnow tracked 8 wire items for XBIT: 4 insider trades, 2 press releases and news items and 2 SEC filings. The most recent was published on November 13, 2026.Is XBIT profitable?
No. XBiotech Inc. reported a net loss of $43.59M for the twelve months ended Sep 30, 2026.How much cash and debt does XBIT have?
XBiotech Inc. reported $105.04M in cash and cash equivalents on its most recent balance sheet in SEC filings.Where does XBIT stock trade?
XBiotech Inc. (XBIT) is listed on NASDAQ.What sector and industry is XBIT in?
XBiotech Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did XBiotech Inc. go public?
XBiotech Inc. (XBIT) completed its IPO in 2015.What companies are similar to XBIT?
Notable peers in the same industry include MGNX (MacroGenics Inc.), AMGN (Amgen Inc.), ABCL (AbCellera Biologics Inc.), VIR (Vir Biotechnology Inc.), XNCR (Xencor Inc.). Compare XBIT side-by-side with any of them on Quantisnow.How can I track XBIT on Quantisnow?
Quantisnow aggregates XBiotech Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow XBIT to receive live email and push alerts on every new disclosure.